>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Newsroom

News of the Hour News Reader Market News Stock News Topics Social Sentiments Market TV Press Releases
Articles > Disease-fighting Companies: Top gainers NVAX, MRNA

Disease-fighting Companies: Top gainers NVAX, MRNA

By KlickAnalytics Data Insights  |   August 31, 2026 04:40PM ET

Following are the Top 5 companies based on their one-day percentage change within the 'Disease-fighting Companies' theme.

Novavax, Inc. (NVAX)
NVAX is trading UP for the last 2 days, and it at trading at $9.39 with volume of 4,685,672 and a one day change of $0.13 (1.42%). Novavax, Inc. has a 52-week low of 6.20 and a 52-week high of $11.97. The business's 50-day moving average price is $8.46 and its 200 day moving average price is $8.48. The firm has a market cap of $2 million, a P/E ratio of -6.09, and a beta of 2.30.

Top news headlines for NVAX

  • Shares of Novavax Inc. (NASDAQ:NVAX) are trading higher Monday morning. The stock is extending its 30% monthly gains as investors respond positively to regulatory approvals across major jurisdictions for its updated protein-based COVID-19 vaccine ahead of the 2026–2027 autumn vaccination campaign, alongside broader sector strength bolstered by positive late-stage oncology clinical trial results across the biotech landscape.

    • For more information on NVAX:
  • Historical Price Targets
  • Hiistorical Analyst Recommendations
  • Earning Price Impact Analysis
  • Seasonality Analysis

    • Moderna, Inc. (MRNA)
    MRNA is trading UP for the last 1 days, and it at trading at $138.81 with volume of 15,103,339 and a one day change of $0.82 (0.60%). Moderna, Inc. has a 52-week low of 22.28 and a 52-week high of $176.66. The business's 50-day moving average price is $76.79 and its 200 day moving average price is $51.76. The firm has a market cap of $55 million, a P/E ratio of -17.29, and a beta of 1.11.

    Top news headlines for MRNA

  • Alyeska Investment Group L.P. cut its stake in shares of Moderna, Inc. (NASDAQ: MRNA) by 86.2% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 560,819 shares of the company's stock after selling 3,490,366 shares during the period. Alyeska Investment Group L.P. owned
  • Shares of Moderna, Inc. (NASDAQ: MRNA - Get Free Report) have received an average rating of "Hold" from the twenty-three research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation and seven have issued a buy recommendation

    • For more information on MRNA:
  • Historical Price Targets
  • Hiistorical Analyst Recommendations
  • Earning Price Impact Analysis
  • Seasonality Analysis

    • This article was generated by KlickAnalytics data insight content engine.

    Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.

    Market News ×
    Loading news…